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many articles have been published on the subject of fna, highlighting the usefulness of flow cytometry 
in the diagnosis and classification of lymphomas. But occasionally, flow cytometric evaluation fails to 
detect an abnormal population in a fna specimen involved by lymphoid neoplasm. sampling errors 
(poor viability, peripheral blood contamination and hypocellular specimens) are the major reasons of this 
failure. in our laboratory we use a simple, fast and cost-effective approach to assess adequacy of fna 
materials and in this paper, we describe this procedure with giving some examples of interpretations of 
our results.
Fine-needle aspiration (FNA) is a simple and painless procedure and FNA materials are very useful tools for the diagnosis classification and 
staging of newly diagnosed and recurrent lymphomas. 
Many articles have been published on the subject of 
FNA, highlighting the usefulness of flow cytometry 
in the diagnosis and classification of lymphomas.1-5 
Flow cytometry is suitable for liquid specimens such as 
blood, bone marrow and serous effusions (for example, 
peritoneal, pleura) which is not the case for the solid tu-
mors such as lymph nodes, spleen, liver, and cutaneous 
nodules, which is why aspirates must be suspended in 
various solutions to analyze them by flow cytometry.
Occasionally, flow cytometric evaluation fails to 
detect an abnormal population in a FNA specimen in-
volved by a lymphoid neoplasm. Sampling errors (poor 
viability, peripheral blood contamination and hypocel-
lular specimens) are the major reasons of this failure.6 
Meda et al analysed 290 aspirates from 275 patients. 
Flow cytometric analysis was impossible in 14 cases 
(4.8%) due to sampling problems (poor viability in 6 
cases, peripheral blood contamination in 5 cases and 
insufficient quantity in 3 cases).7  According to Young 
et al, five FNAs out of 107 (4.7%) were deemed inad-
equate for diagnosis because of insufficient cellularity 
and were excluded from the study.8 Zeppa et al studied 
307 FNAs in which 15 cases (4.9%) were inadequate 
for flow cytometric analysis.2
In our laboratory we use a simple, fast and cost-effec-
tive approach to assess the adequacy of FNA materials 
and we describe this procedure, giving some examples 
of interpretations of our results.
Sampling technique
The FNA of subcutaneous lymph nodes and tumors 
are performed in the outpatient setting according to 
described methods.9,10 Using a 30-gauge hypodermic 
needle with a 1mL syringe attached, we fixate the lymph 
node between two fingers of the free hand, insert the 
needle into the node, and apply forceful suction to aspi-
rate a small amount of material from several locations, 
changing the angle of the needle slightly. The needle is 
removed if blood or cellular material is observed within 
the hub. Suction is maintained while the needle is with-
drawn into the subcutis. Fine needle aspirates are di-
luted in a tube containing K3EDTA and 2 mL of phos-
phate-buffered saline (PBS) or RPMI medium.  The 
cell suspension is then strained through a 35µm nylon 
mesh filter to remove large debris and clumps of cells. 
In our experience, the cellular material obtained by 
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Figure 2. FnA sample of a patient with a diffuse large B-cell 
lymphomas: notice that there is an admixture of apoptotic bodies 
(less than 0 fL) small lymphoid cells (5 to 90 fL) and large 
lymphoid cells (more than 90 fl).
Figure 3. WBC histogram demonstrating only apoptotic bodies: 
notice that the majority of cells are smaller then 50 fL and that 
the peak does not start at the base line.
this method, contains more than one million viable lym-
phoid cells with few apoptotic bodies. In comparison to 
the so-called Zajicek or pipette technique which uses a 
needle alone without a syringe to gather more necrotic 
and apoptotic bodies.11,12
Quality control of the sample
An automated cell count of the sample is performed 
using an impedance cell counter (Coulter ACT Diff ). 
This instrument demonstrates a three part predifferen-
tiation leukocyte histogram, which is very helpful in as-
sessing cellularity, blood contamination, lymphoid cells 
size and viability. 
Cellularity 
The specimen requirements of flow cytometry may vary 
somewhat from laboratory to laboratory. With highly 
cellular specimens, the common practice is to stain 1 
million cells per tube, with data collected for 10 000 to 
30 000 events. However, specimens with lower cellular-
ity still may be amenable to analysis. At a minimum, ap-
proximately 50 000 cells per tube are needed to analyze 
10 000 events. If a specimen contains a pure lymphoma 
population, even fewer cells may suffice for diagnosis.13 
In our laboratory, the policy is that the sample must 
contain at least 1000 lymphoid cells /µL. If 1000 lym-
phoid cells /µL are not available, another aspiration is 
immediately applied and rinsed into the sample.  
Peripheral blood contamination
The majority of our samples contain an average of 104 
to 2×104 erythrocytes/µL but it is predictable that 
the samples will enclose some red blood cells as we are 
applying forceful suction to aspirate a small amount 
of material. However the “lyse and wash” procedure 
will get rid of these red cells and the multi-parametric 
gating strategies will allow us to exclude the reactive 
lymphoid cells from the analysis. In our laboratory we 
prefer to evaluate blood contamination by calculating 
the granulocyte/lymphoid cell ratio, which must be 
lower than 0.2, because in samples with more lym-
phoid cells do not cause any problem during the cy-
tometric analysis even if they are mixed with reactive 
or peripheral cells.   
Cell size 
Gong et al tried to evaluate the cell size of the neoplastic 
population by comparing them with the T-cell popu-
lation on forward scatter histogram (FSC-H).14 But 
many authors agree with the fact that large neoplastic 
cells are often disrupted during FNA and processing for 
flow cytometry.7,13
In one series of FNA studies for the primary diagno-
sis of lymphadenopathy, 27% of the cases that ultimately 
were shown to be large B-cell lymphomas initially were 
found to be negative for malignancy by flow cytome-
try.15 In such cases, the examination of forward-scatter 
versus side-scatter plots demonstrated that large cells 
Figure 1. FnA sample of a patient with a mantel zone lymphoma: 
notice that there are no apoptotic bodies and cell sizes are 
included between 5 and 90 fL.
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usually are markedly reduced or absent, in comparison 
with their frequency on cytologic preparations. That is 
why in our unit we prefer to assess cell size before cyto-
metric processing by examining the 3 part pre-differen-
tial leukocytes histogram.
Size-referenced white blood cell (WBC) histograms 
display the classification of leukocytes according to size 
following lysis, not the native cell size. The lytic agent 
lyses the cell and the cytoplasm collapses around the nu-
cleus, producing differential shrinkage. The histogram 
subpopulations reflect the sorting of the cells by their 
relative size, which is primarily their nuclear size. The 
differentiation is as follows: lymphocytes (35-90 fL), 
mononuclear (90-160 fL) and granulocyte (160-450 
fL).16   Figure 1 shows a WBC histogram in a patient 
with a mantel zone lymphoma, and in which the entire 
population falls in the lymphocyte area (between 35 and 
90 fL). Figure 2 shows a WBC histogram in a woman 
with a diffuse large B-cell lymphomas in which we found 
an admixture of small cells and large neoplastic cells 
measuring more than 90 fL and even reaching 200 fL.
Viability  
The most classic methods of assessing cell viability are 
through the use of vital dyes. These are based on the loss 
of membrane integrity of dying cells; allowing access to 
dye that cannot penetrate a living cell.17 The trypan blue 
technique is a noncytometric method in which the stain 
is mixed with the sample, and only the nonviable cells 
take up the stain. Nonviable blue-colored cells are then 
counted manually by light microscopy.17-19
By using the cytometric methods, viability may be 
assessed simultaneously with the analysis of surface 
marker expression using dyes such as propidium io-
dide (PI) or 7-amino-actinomycin D (7-AAD). These 
real-time methods have the advantage of excluding even 
small numbers of dead cells from analysis without the 
need for tedious separation procedures.7,19,20
It is important to note that during the early stages 
of apoptosis and necrosis, the size of cells decreases, ei-
ther through a change in the refractive index of the cell 
(apoptosis) or through cell shrinkage (necrosis).19 That 
is why the 3-part pre-differential leukocytes histogram 
is a helpful way to assess viability.
In the case of FNA gathering a large amount of 
apoptotic bodies (Figure 3), the WBC histogram will 
demonstrate a lymph peak that does not start at base-
line with a mean event size lower than 30 fL. For aspi-
rates that contain only viable cells (Figure 1), the lymph 
peak will start at baseline with size of cell larger than 35 
fL.  This method is a simple, fast and cost-effective way 
to screen cell viability, even if it is not so precise as the 
trypan blue or real-time methods 
In conclusion, the pre-differentiation histogram of 
the lymphoid cells sampled by FNA is a helpful way to 
screen cell size of the lymphoid neoplasic population 
and adequacy of the aspirate specimen for flow cyto-
metric analysis.
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